PharmaDrug receives encouraging potency data for candidate DMT-analogue molecules designed to treat primary open angle glaucoma Terasaki Institute advances PharmaDrug’s candidate DMT-analogue molecules into next phase...
Patent claims on synergistic application of cepharanthine, cabazitaxel and other taxane family members used in combination to treat primary, metastatic and chemotherapy-resistant prostate cancer Expands on...
Establishing cGMP supply for IND-enabling and up to Phase 2 clinical studies for PD-001 oral formulation for esophageal cancer and mild to moderate COVID-19 Toronto, Ontario–(Newsfile...
Toronto, Ontario–(Newsfile Corp. – January 24, 2022) – PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (FSE: G111) (“PharmaDrug” or the “Company“), a specialty pharmaceutical company focused on...
Toronto, Ontario–(Newsfile Corp. – January 20, 2022) – PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (“PharmaDrug” or the “Company“), a specialty pharmaceutical company focused on the development...
Toronto, Ontario–(Newsfile Corp. – January 13, 2022) – PharmaDrug Inc. (CSE: PHRX) (OTC: LMLLF) (“PharmaDrug” or the “Company“), a specialty pharmaceutical company focused on the development...
Toronto, Ontario–(Newsfile Corp. – December 13, 2021) – PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (“PharmaDrug” or the “Company“), a specialty pharmaceutical company focused on the development...
Established alignment with FDA on the path forward for the development of PD-001, a patented enteric-coated formulation of cepharanthine, towards clinical studies for mild-moderate COVID-19 infection...
Results of the 4 cancer types where cepharanthine provides exceptional potency and/or synergistic inhibitory effects when combined with standard of care (SoC) chemotherapy provides support for...
PharmaDrug narrows list of candidate tryptamine molecules for the treatment of primary open angle glaucoma (PAOG) Terasaki Institute receives PharmaDrug’s two candidate DMT analogue molecules Terasaki...